Quality of life in schizophrenia and drug formulary restriction

Drug Benefit Trends

Volumn 14, Issue SUPPL. E, 2002, Pages 32-34

  Pomerantz, Jay M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antipsychotic agents; Pharmacotherapy; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ALCOHOLISM; ANXIETY DISORDER; AUDITORY HALLUCINATION; CLINICAL TRIAL; COMORBIDITY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; HEALTH CARE ACCESS; HUMAN; MAJOR DEPRESSION; MEDICAID; MEDICAL ASSESSMENT; NEGATIVE SYNDROME; OUTCOMES RESEARCH; PANIC; PATIENT SATISFACTION; POVERTY; PRESCRIPTION; PSYCHOSIS; QUALITY OF LIFE; RATING SCALE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL SUPPORT; SOCIETY; SOCIOECONOMICS; SUICIDE ATTEMPT; WELLBEING;

EID: 0036964022     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Karow A, Naber D. Psychosocial outcomes in patients with schizophrenia: Quality of life and reintegration. Curr Opin Psychiatry. 2002;15:31-36.
2. Franz M, Meyer T, Reber T, Gallhofer B. The importance of social comparisons for high levels of subjective quality of life in chronic schizophrenic patients. Qual Life Res. 2000;9:481-489.
3. Awad AG, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation. Qual Life Res. 1997;6:21-26.
4. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388-398.
5. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50:79-88.
6. Wilkinson G, Hesdon B, Wild D, et al. Self-report quality of life measure for people with schizophrenia: The SQLS. Br J Psychiatry. 2000;177:42-46.
7. Meltzer HY. Outcome in schizophrenia: Beyond symptom reduction. J Clin Psychiatry. 1999; 60 (suppl 3):3-8.
8. Revicki DA, Genduso LA, Hamilton SH, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: Quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res. 1999;8:417-426.
9. Franz M, Lis S, Pluddemann K, Gallhofer B. Conventional versus atypical neuroleptics: Subjective quality of life in schizophrenic patients. Br J Psychiatry. 1997;170:422-425.
10. Rascati KL. Beyond efficacy: Consideration of humanistic outcomes. Drug Benefit Trends. 2001;13(suppl D):13-15, 28.
11. Hamilton SH, Edgell ET, Revicki DA, Breier A. Functional outcomes in schizophrenia: A comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol. 2000;15:245-255.
12. Olfson M, Lewis-Fernandez R, Weissman MM, et al. Psychotic symptoms in an urban general medicine practice. Am J Psychiatry. 2002;159:1412-1419.
13. Leslie DL, Rosenheck RA. From conventional to atypical antipsychotics and back: Dynamic processes in the diffusion of new medications. Am J Psychiatry. 2002;159:1534-1540.
14. Mulligan K. Vermont gives formulary exemption to psychiatric drugs. Psychiatric News. August 16, 2002 4-5. Available at: http://www.leg.state.vt.us/docs/2002/acts/ACT127.HTM. Accessed October 13, 2002.
15. Nuttbrock LA, Rosenblum A, Magura S, McQuistion HL. Psychotic ideation and receipt of government entitlements among homeless persons in New York City. Psychiatr Serv. 2002;53:719-723.